Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Attovia Therapeutics, Inc.ATTO · Entity 4984 | Director · President and CEO | August 04, 2026 | October 09, 2026 |
| PORTOLA PHARMACEUTICALS INCPTLA · Entity 147987 | EVP, CBO | August 31, 2018 | September 05, 2018 |
| Zai Lab LtdZLAB · Entity 4271 | Director · President & COO | October 28, 2021 | October 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Attovia Therapeutics, Inc.
Report date August 04, 2026 · Filed October 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-08-03 | Direct | 538,300 |
Reported balance
After 2026-08-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-04 · Grant · Acquired 538,300 · Balance 538,300 F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
PORTOLA PHARMACEUTICALS INC
Report date August 31, 2018 · Filed September 05, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,043 |
Ending reported balance
After 2018-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-31 · Exercise / conversion · Acquired 20,000 · Balance 87,196 F1: Each Performance Stock Unit ("PSU") granted on June 15, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 5,000 of the PSUs vested July 28, 2018 and 20,000 vested on August 31, 2018. Row 2 · 2018-09-04 · Tax withholding · Disposed 10,153 · Balance 77,043 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Each Performance Stock Unit ("PSU") granted on June 15, 2015 pursuant to the Issuer's 2013 Equity Incentive Plan represented a contingent right to receive one share of Issuer's Common Stock. These PSUs were earned based on achievement of the market performance conditions and were subject to an additional one year period of service. 5,000 of the PSUs vested July 28, 2018 and 20,000 vested on August 31, 2018.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Zai Lab Ltd
Report date October 28, 2021 · Filed October 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 77,500 |
Last balance in matching sequence
After 2021-10-28 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2021-10-28 · Sale · Disposed 2,065 · Balance 85,435 F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2: Reflects a weighted average sale price of $104.49 per share, at prices ranging from $103.77 to $104.76 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4: Shares held by Reporting Person's spouse. Row 3 · 2021-10-28 · Sale · Disposed 7,935 · Balance 77,500 F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3: Reflects a weighted average sale price of $105.13 per share, at prices ranging from $104.87 to $105.40 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4: Shares held by Reporting Person's spouse. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 187,668 |
Reported balance
Holding disclosure · report date 2021-10-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 187,668 |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2: Reflects a weighted average sale price of $104.49 per share, at prices ranging from $103.77 to $104.76 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Reflects a weighted average sale price of $105.13 per share, at prices ranging from $104.87 to $105.40 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4: Shares held by Reporting Person's spouse.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Oct 9, 2026 00:00 UTC Amendment | Attovia Therapeutics, Inc. ATTO · Entity 4984 | GrantStock Option (Right to Buy) · Derivative | 538,300 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001644888-26-000009 · form4a-10092026_121054.xml · derivative · entry 1 Fu Tao · CIK 0001644888 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,300 Underlying: Common Stock · 538,300 shares Expires 2036-08-03 F1 · derivative.exercise_date: 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 17:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 7,935 | $105.13 | $834,206.55 |
DisclosureSEC source: 0001567619-21-019018 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 77,500 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $105.13 per share, at prices ranging from $104.87 to $105.40 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 17:15 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,065 | $104.49 | $215,771.85 |
DisclosureSEC source: 0001567619-21-019018 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 85,435 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $104.49 per share, at prices ranging from $103.77 to $104.76 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F4 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| October 14, 2021 Filed Oct 14, 2021 20:40 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,400 | $103.44 | $144,816.00 |
DisclosureSEC source: 0001567619-21-018320 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 87,500 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $103.44 per share, at prices ranging from $103.43 to $103.50 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| October 14, 2021 Filed Oct 14, 2021 20:40 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 5,240 | $102.90 | $539,196.00 |
DisclosureSEC source: 0001567619-21-018320 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 88,900 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $102.90 per share, at prices ranging from $102.42 to $103.38 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| October 14, 2021 Filed Oct 14, 2021 20:40 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,360 | $102.02 | $342,787.20 |
DisclosureSEC source: 0001567619-21-018320 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 94,140 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $102.02 per share, at prices ranging from $101.40 to $102.27 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F5 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 17:37 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 250 | $108.85 | $27,212.50 |
DisclosureSEC source: 0001567619-21-017761 · doc1.xml · nonDerivative · entry 5 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 97,500 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: Reflects a weighted average sale price of $108.85 per share, at prices ranging from $108.55 to $108.93 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 17:37 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,417 | $107.85 | $260,673.45 |
DisclosureSEC source: 0001567619-21-017761 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 97,750 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $107.85 per share, at prices ranging from $107.45 to $108.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 17:37 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,619 | $106.73 | $492,985.87 |
DisclosureSEC source: 0001567619-21-017761 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 100,167 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $106.73 per share, at prices ranging from $106.30 to $107.21 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 17:37 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,714 | $105.55 | $286,462.70 |
DisclosureSEC source: 0001567619-21-017761 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 104,786 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person's spouse, dated June 17, 2021, expires February 28, 2022 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $105.55 per share, at prices ranging from $105.20 to $106.20 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares held by Reporting Person's spouse. Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 17:58 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Tax withholdingOrdinary Shares | 19,832 | $119.86 | $2,377,063.52 |
DisclosureSEC source: 0001567619-21-017605 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,668 F2 · balance_after: The reported transaction involved the withholding of 19,832 shares upon the vesting of 40,000 restricted shares in order to pay associated taxes. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · derivative · entry 10 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F10 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 400 | $133.07 | $53,228.00 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 8 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,600 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F8 · price: Reflects a weighted average sale price of $133.07 per share, at prices ranging from $132.74 to $133.50 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,300 | $132.25 | $171,925.00 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 7 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,000 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F7 · price: Reflects a weighted average sale price of $132.25 per share, at prices ranging from $131.66 to $132.66 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 574 | $130.64 | $74,987.36 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 6 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,300 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F6 · price: Reflects a weighted average sale price of $130.64 per share, at prices ranging from $130.33 to $131.25 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,007 | $129.29 | $130,195.03 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 5 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,874 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: Reflects a weighted average sale price of $129.29 per share, at prices ranging from $128.84 to $129.67 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,541 | $128.33 | $197,756.53 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,881 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $128.33 per share, at prices ranging from $127.81 to $128.75 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,100 | $125.96 | $390,476.00 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,422 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $125.96 per share, at prices ranging from $125.66 to $126.60 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,978 | $124.98 | $247,210.44 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,522 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $124.98 per share, at prices ranging from $124.54 to $125.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:59 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 10,000 | $18.92 | $189,200.00 |
DisclosureSEC source: 0001567619-21-017211 · doc1.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| September 15, 2021 Filed Sep 27, 2021 17:58 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 100 | $134.09 | $13,409.00 |
DisclosureSEC source: 0001567619-21-017605 · doc1.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,500 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 19:12 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001567619-21-016385 · doc1.xml · derivative · entry 7 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F7 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 19:12 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 200 | $144.51 | $28,902.00 |
DisclosureSEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 5 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F5 · price: Reflects a weighted average sale price of $144.51 per share, at prices ranging from $144.45 to $144.56 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 19:12 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,894 | $143.76 | $559,801.44 |
DisclosureSEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,200 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F4 · price: Reflects a weighted average sale price of $143.76 per share, at prices ranging from $143.32 to $144.22 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 19:12 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,306 | $142.71 | $614,509.26 |
DisclosureSEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,094 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F3 · price: Reflects a weighted average sale price of $142.71 per share, at prices ranging from $142.21 to $143.18 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 19:12 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,600 | $141.92 | $227,072.00 |
DisclosureSEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,400 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 F2 · price: Reflects a weighted average sale price of $141.92 per share, at prices ranging from $141.20 to $142.16 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 19:12 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 10,000 | $18.92 | $189,200.00 |
DisclosureSEC source: 0001567619-21-016385 · doc1.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934 Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · derivative · entry 9 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F7 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 100 | $175.00 | $17,500.00 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 7 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $170.30 per share, at prices ranging from $169.81 to $170.64 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,265 | $174.26 | $568,958.90 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 6 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,100 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: Reflects a weighted average sale price of $174.26 per share, at prices ranging from $173.94 to $174.80 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 3,281 | $173.56 | $569,450.36 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 5 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,365 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $173.56 per share, at prices ranging from $172.94 to $173.93 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 21 | $171.89 | $3,609.69 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,646 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,000 | $171.36 | $171,360.00 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,667 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $171.36 per share, at prices ranging from $170.89 to $171.88 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,333 | $170.30 | $397,309.90 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,667 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $170.30 per share, at prices ranging from $169.81 to $170.64 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 18:02 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 10,000 | $18.92 | $189,200.00 |
DisclosureSEC source: 0001567619-21-013659 · doc1.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · derivative · entry 9 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F9 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 701 | $169.12 | $118,553.12 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · nonDerivative · entry 7 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F7 · price: Reflects a weighted average sale price of $169.12 per share, at prices ranging from $168.82 to $169.41 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 300 | $167.74 | $50,322.00 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · nonDerivative · entry 6 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,701 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F6 · price: Reflects a weighted average sale price of $167.74 per share, at prices ranging from $167.56 to $168.10 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 607 | $166.65 | $101,156.55 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · nonDerivative · entry 5 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,001 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · price: Reflects a weighted average sale price of $166.65 per share, at prices ranging from $166.51 to $167.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,476 | $165.78 | $244,691.28 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,608 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F4 · price: Reflects a weighted average sale price of $165.78 per share, at prices ranging from $165.40 to $166.11 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 4,564 | $164.80 | $752,147.20 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,084 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $164.80 per share, at prices ranging from $164.38 to $165.35 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,352 | $164.08 | $385,916.16 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,648 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $164.08 per share, at prices ranging from $163.38 to $164.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 10,000 | $18.92 | $189,200.00 |
DisclosureSEC source: 0001567619-21-012382 · doc1.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 26, 2021 Filed May 26, 2021 20:20 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001567619-21-011218 · doc1.xml · derivative · entry 7 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F5 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. Read SEC document |
| May 26, 2021 Filed May 26, 2021 20:20 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 1,000 | $161.37 | $161,370.00 |
DisclosureSEC source: 0001567619-21-011218 · doc1.xml · nonDerivative · entry 5 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,000 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 26, 2021 Filed May 26, 2021 20:20 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 300 | $160.14 | $48,042.00 |
DisclosureSEC source: 0001567619-21-011218 · doc1.xml · nonDerivative · entry 4 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,000 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| May 26, 2021 Filed May 26, 2021 20:20 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 5,887 | $159.44 | $938,623.28 |
DisclosureSEC source: 0001567619-21-011218 · doc1.xml · nonDerivative · entry 3 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,300 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: Reflects a weighted average sale price of $159.44 per share, at prices ranging from $159.02 to $159.99 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 26, 2021 Filed May 26, 2021 20:20 UTC | Zai Lab Ltd ZLAB · Entity 4271 | SaleOrdinary Shares | 2,813 | $158.55 | $446,001.15 |
DisclosureSEC source: 0001567619-21-011218 · doc1.xml · nonDerivative · entry 2 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,187 F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: Reflects a weighted average sale price of $158.55 per share, at prices ranging from $157.95 to $158.84 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 26, 2021 Filed May 26, 2021 20:20 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionOrdinary Shares | 10,000 | $18.92 | $189,200.00 |
DisclosureSEC source: 0001567619-21-011218 · doc1.xml · nonDerivative · entry 1 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 20:01 UTC | Zai Lab Ltd ZLAB · Entity 4271 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001567619-21-008430 · doc1.xml · derivative · entry 6 Fu Tao · CIK 0001644888 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,000 Underlying: Ordinary Shares · 10,000 shares Expires 2028-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F6 · derivative.exercise_date: The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.